BLTE vs. BBIO, OGN, IONS, CYTK, APLS, MDGL, ALPN, NUVL, ALKS, and PRGO
Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include BridgeBio Pharma (BBIO), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
BridgeBio Pharma (NASDAQ:BBIO) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, community ranking, profitability, dividends, earnings and media sentiment.
BridgeBio Pharma received 121 more outperform votes than Belite Bio when rated by MarketBeat users. However, 95.83% of users gave Belite Bio an outperform vote while only 68.25% of users gave BridgeBio Pharma an outperform vote.
BridgeBio Pharma has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.52, indicating that its share price is 252% less volatile than the S&P 500.
Belite Bio has lower revenue, but higher earnings than BridgeBio Pharma. Belite Bio is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.
99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 24.7% of BridgeBio Pharma shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, BridgeBio Pharma had 9 more articles in the media than Belite Bio. MarketBeat recorded 15 mentions for BridgeBio Pharma and 6 mentions for Belite Bio. BridgeBio Pharma's average media sentiment score of 0.64 beat Belite Bio's score of 0.47 indicating that Belite Bio is being referred to more favorably in the news media.
Belite Bio has a net margin of 0.00% compared to Belite Bio's net margin of -246.24%. Belite Bio's return on equity of 0.00% beat BridgeBio Pharma's return on equity.
BridgeBio Pharma currently has a consensus target price of $47.62, suggesting a potential upside of 69.99%. Belite Bio has a consensus target price of $44.83, suggesting a potential downside of 8.41%. Given Belite Bio's higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Belite Bio.
Summary
BridgeBio Pharma beats Belite Bio on 11 of the 18 factors compared between the two stocks.
Get Belite Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belite Bio Competitors List
Related Companies and Tools
